The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping

The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping

Bronchiectasis is a heterogeneous airway disease with diverse causes, making precise diagnosis, prognosis, and treatment response prediction challenging. Identifying patient subgroups (phenotypes) and molecular profiles (endotypes) can enhance individualized assessment and management. While prior studies, primarily in European populations, have identified key phenotypes and endotypes, their relevance to Chinese patients remains unclear due to geographic and clinical differences. Specific causes of bronchiectasis, such as allergic bronchopulmonary aspergillosis (ABPA) and primary ciliary dyskinesia (PCD), may also exhibit distinct pathophysiology requiring further exploration. The C-BRIDGE Study seeks to characterize phenotypes and endotypes in Chinese bronchiectasis patients during stable disease and exacerbations, evaluate differences in clinical outcomes across these subgroups, and develop personalized medicine strategies based on these findings, applicable in China and globally.

Primary Objective: To identify molecular endotypes of bronchiectasis that accurately predict prognosis and guide treatment responses.

Secondary Objectives:

To characterize molecular endotypes of stable bronchiectasis in Chinese patients.

To define molecular endotypes of bronchiectasis exacerbations in Chinese patients.

To investigate molecular endotypes specific to allergic bronchopulmonary aspergillosis (ABPA).

To explore genotypes and inflammatory endotypes of cystic fibrosis (CF) and primary ciliary dyskinesia (PCD) in Chinese patients.

To validate candidate biomarkers for stable and exacerbation endotypes to support stratified medicine.

To conduct in vivo or in vitro proof-of-concept studies using phenotypic data to identify patient subgroups likely to benefit from specific pharmacological interventions.

Study Design: This observational cohort study will link identified patient subgroups with meaningful clinical outcomes to inform prognosis and optimize treatment strategies.

Bronchiectasis is a common, heterogeneous chronic airway disease that remains understudied in clinical and translational research. Although several phenotypes and endotypes have been identified-primarily in European populations-data from Chinese patients are limited. Racial and geographic differences suggest that bronchiectasis phenotypes and endotypes in China may differ from those in Western cohorts. Recent controlled trials have failed to meet primary endpoints, likely due to insufficient identification of patient subgroups that optimally respond to antibiotics, mucoactive agents, or anti-inflammatory therapies. The C-BRIDGE Study seeks to address this gap by exploring the clinical, genomic, microbiological, inflammatory, and functional heterogeneity of bronchiectasis in Chinese patients to define molecular endotypes for stratified assessment and management.

Study Aims and Objectives:

1. Characterize molecular endotypes of stable bronchiectasis in Chinese patients.
2. Identify molecular endotypes of bronchiectasis exacerbations in Chinese patients.
3. Investigate molecular endotypes in patients with allergic bronchopulmonary aspergillosis (ABPA).
4. Develop a screening algorithm and elucidate genotypes and inflammatory endotypes of cystic fibrosis (CF) and primary ciliary dyskinesia (PCD) in China.
5. Validate candidate biomarkers for stable and exacerbation endotypes to enable stratified medicine.
6. Perform in vivo and in vitro proof-of-concept studies using phenotypic data to pinpoint patient subgroups likely to benefit from specific pharmacological treatments.

Study Design:

Observational cohort study.

Study Methods:

A target of 1,500 patients with bronchiectasis will be recruited across participating centers for an observational study with the following aims:

Aim 1: Stable Disease Endotyping Up to 1,500 patients will be studied to define and validate endotypes of stable bronchiectasis. Data collection will include clinical assessments, sputum and nasal microbiome analysis, sputum proteomics, nasal and airway transcriptomics, single-cell sequencing of bronchoalveolar lavage fluid (BALF), and measurement of inflammatory markers in systemic, nasal, sputum, and BALF samples. A sub-study (n=100) will use air-liquid interface cultures of primary airway epithelial cells to assess responses to various stimuli and pharmacological interventions.

Aim 2: Exacerbation Endotyping A subset of 200 patients will be evaluated during exacerbations to replicate the phenotyping approach. This will involve analyzing changes from baseline in microbiome, proteomics, metabolomics, and other markers to identify clusters linked to exacerbation onset, progression, and outcomes.

Aim 3: Allergic Bronchopulmonary Aspergillosis (ABPA) Subgroup Analysis A subset of 150 patients with ABPA will be studied to investigate molecular endotypes by integrating single-cell sequencing, microbiome, mycobiome, proteomics, metabolomics, and other markers to identify clusters associated with exacerbation, recurrence, and treatment responses.

Aim 4: Idiopathic Bronchiectasis and Genetic Screening Patients with idiopathic bronchiectasis will be screened for cystic fibrosis, CFTR-related disorders, and primary ciliary dyskinesia (PCD) to identify genotypes and inflammatory endotypes. This will integrate genomics, microbiome, proteomics, and metabolomics to explore associations among phenotypes, genotypes, endotypes, and prognosis.

Aim 5: Biomarker Validation and Prediction Model Development Candidate phenotypes and endotypes will be externally validated using registered, ethically approved biobanks. Validated biomarkers will be correlated with clinically meaningful outcomes, such as treatment responses, to enable their use in stratified medicine. Clinical data and validated biomarkers will be integrated to construct and validate prediction models for exacerbation frequency, time to first exacerbation, and lung function decline.

Participants will visit the Clinical Research Centre at least once for sampling and clinical data collection, with consent obtained to link their samples to the C-BRIDGE database.

Ethics Approval:

Approved by the Ethics Committee of Shanghai Pulmonary Hospital and other participating centers.

Expected Outcomes:

The C-BRIDGE Study will establish detailed molecular endotypes of bronchiectasis in Chinese patients, facilitating precise prognosis prediction and tailored treatment strategies. By identifying and validating patient subgroups and biomarkers, it will provide a foundation for personalized medicine in bronchiectasis management, with potential relevance in China and worldwide.

Inclusion Criteria:

• A prior CT scan confirming bronchiectasis, accompanied by a compatible clinical syndrome including cough, sputum production, and/or recurrent respiratory tract infections.
• At the screening visit, participants must have been clinically stable for 4 weeks, defined as no antibiotic or corticosteroid treatment for a pulmonary exacerbation in the preceding 4 weeks.

Exclusion Criteria:

• Inability to provide informed consent
• Age under 18 years
• Patients with active tuberculosis
• Use of antibiotics or corticosteroids for a pulmonary exacerbation within the past 4 weeks